Evidence map›Paper›PMID 25245963›Full record

ReviewThe Surgical clinics of North America2014

Surviving cutaneous melanoma: a clinical review of follow-up practices, surveillance, and management of recurrence.

Amy A Mrazek, Celia Chao

Abstract readReview
In one paragraph

Review in The Surgical clinics of North America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. The Economic Value of MR-Imaging for Uveal Melanoma.Clinical ophthalmology (Auckland, N.Z.) · 2020
    Article
  7. Article
  8. Article
  9. Metabolomic identification of diagnostic serum-based biomarkers for advanced stage melanoma.Metabolomics : Official journal of the Metabolomic Society · 2018
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Amy A MrazekDepartment of Surgery, University of Texas Medical Branch, 301 University Boulevard, Route 0534, Galveston, TX 77555, USA.
Celia ChaoDepartment of Surgery, University of Texas Medical Branch, 301 University Boulevard, Route 0737, Galveston, TX 77555, USA. Electronic address: cechao@utmb.edu.

Funding

SURGICAL TRAINING IN GASTROINTESTINAL ENDOCRINOLOGYT32DK007639 · NIDDK · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI RADHAKRISHNAN, RAVI S. · 1992 to 2022
$3.6M
Bombesin-Activated Carcinoma Associated Fibroblasts in Colorectal CancerK08CA125209 · NCI · UNIVERSITY OF TEXAS MED BR GALVESTON · PI CHAO, CELIA · 2009 to 2013
$643k
NCI NIH HHS K08 CA125209NIDDK NIH HHS T32 DK007639
6 · The paper itself

Abstract

The number of melanoma survivors in the United States continues to steadily increase 2.6% per year, while death rates have remained stable over time. Although controversy exists regarding optimal surveillance strategies, recommendations for clinical monitoring are based on tumor stage, tumor phenotype, likelihood of recurrence, prognosis, risk factors, psychosocial impact of disease, and patient well-being. Management guidelines for recurrent disease depend on the type of recurrence: local, satellite/in-transit, regional, or distant metastasis. This article is a current review of the literature concerning melanoma survivorship.

Indexed as

Adaptation, PsychologicalAnxietyCicatrixEarly Detection of CancerFemaleHumansLong-Term CareMaleMelanomaNeoplasm Recurrence, LocalPatient-Centered CarePatient Education as TopicPractice Guidelines as TopicPrognosisRisk Reduction BehaviorSkin NeoplasmsManagement of recurrenceMelanoma survivorshipSurveillance and follow-upSurvival prognosis

Identifiers

PMID25245963
PMCPMC4173121

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.